Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: arnie h who wrote (1840)	5/25/2005 11:59:59 AM
From: richardred	Read Replies (2) \| Respond to of 2173

I'm in for a buy/ write today. Just guessing, but, I think a wild card down the road for this stock could be a new partner in the development of it's NDA's for obesity. Lilly needs to be kept in check. I think it could be done without damaging it's Lilly relationship. It would also give a needed expanded market for Symlin to live up to it's potential. As AMLN won't be making money in the bottom line for some time. Fining new partners to share costs will be key and IMO help this stock. It sure would be ironic if J & J came back into the picture. Amgen, Abbott, or Novartis could be good partners.